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Abstract
Human RCAN3 (regulator of calcineurin 3) belongs to the human RCAN gene family. In this study we provide, with in silico
and in vitro analyses, the first detailed description of the human multi-transcript RCAN3 locus. Its analysis revealed that it is
composed of a multigene system that includes at least 21 RCAN3 alternative spliced isoforms (16 of them identified here for
the first time) and a new RCAN3 antisense gene (RCAN3AS). In particular, we cloned RCAN3-1,3,4,5 (lacking exon 2), RCAN3-
1a,2,3,4,5, RCAN3-1a,3,4,5, RCAN3-1b,2,3,4,5, RCAN3-1c,2,3,4,5, RCAN3-1c,2,4,5 and RCAN3-1c,3,4,5, isoforms that present a
different 59 untranslated region when compared to RCAN3. Moreover, in order to verify the possible 59 incompleteness of
previously identified cDNA isoforms with the reference exon 1, ten more alternative isoforms were retrieved. Bioinformatic
searches allowed us to identify RCAN3AS, which overlaps in part with exon 1a, on the opposite strand, for which four
different RCAN3AS isoforms were cloned. In order to analyze the different expression patterns of RCAN3 alternative first
exons and of RCAN3AS mRNA isoforms, RT-PCR was performed in 17 human tissues. Finally, analyses of RCAN3 and RCAN3AS
genomic sequences were performed to identify possible promoter regions, to examine donor and acceptor splice
sequences and to compare evolutionary conservation, in particular of alternative exon 1 or 1c - exon 2 junctions in different
species. The description of its number of transcripts, of their expression patterns and of their regulatory regions can be
important to clarify the functions of RCAN3 gene in different pathways and cellular processes.
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Introduction
RCAN(regulatorofcalcineurin)humangenefamilyincludesthree
members: RCAN1 (also known as DSCR1 - Down syndrome critical
region gene 1 - [1], MCIP1, CALP1, ADAPT78), RCAN2 (also known
as ZAKI-4 - [2], DSCR1L1, MCIP2, CALP2) and RCAN3 (also known
as DSCR1L2 - [3], MCIP3, CALP3), the studied gene in the present
work.
The novel denomination for RCAN genes and proteins has
recently been approved by the HUGO Gene Nomenclature
Committee, and due to the large number of human RCAN mRNA
isoforms, a specific nomenclature was proposed: RCAN1, RCAN2
or RCAN3 - followed by the hitherto identified exon numbers [4].
All three RCAN gene products have been demonstrated to
interact with and inhibit calcineurin [5–7], a Ca
2+/calmodulin-
activated serine/threonine phosphatase that is involved in the
transcriptional activation of many target genes. In particular,
calcineurin activation causes nuclear factor of activated T-cells
(NFAT) transcription factors translocation to the nucleus, where,
in cooperation with other transcription factors, they induce genes
expression. A calcineurin inhibitor RCAN motif (RCAN CIC) has
been demonstrated to bind calcineurin [8], whose signalling plays
a role in many physiological and pathological processes, including
cardiac hypertrophy [9,10], T-cell activation and cytokine gene
expression [11,12], skeletal myocyte differentiation and fibre-type
switching [13,14], synaptic plasticity or neurotransmission [15,16],
cell apoptosis [17] and endometrial adenocarcinoma regulation
[18]. Recently, the RCAN3 inhibitory role on human umbilical
vein endothelial cells (HUVEC) proliferation, both basally and
under vascular endothelial growth factor or phorbol 12-myristate
13-acetate stimulation conditions, has been demonstrated. This
process is probably mediated by calcineurin signalling and
independent from the inflammatory and angiogenic processes
[19]. Moreover, we demonstrated that RCAN3 also interacts with
TNNI3 [20], the human inhibitory cardiac troponin that prevents
contraction in the absence of calcium and troponin C [21]. RCAN3
exon 2 product has been found to be sufficient for binding TNNI3
[20,22].
RCAN3 is the most recently identified member of the human
RCAN gene family, appearing only in vertebrates, in agreement
with the fact that the number of RCAN members tends to increase
in more complex organisms [23]. RCAN3 gene (GenBank
accession number: NM_013441) [24] is localized on chromosome
1 (1p36.11), it is composed of five exons and the coding sequence,
included between exon 2 and exon 5, encodes for a 241 amino
acid predicted protein (estimated molecular weight 27.5 kilodalton
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the FLISPP motif, comprising the signature of the family [3]. Due
to the fact that RCAN3 mRNA is the first identified isoform, in the
present work we refer to RCAN3 as the reference isoform under the
name RCAN3-1,2,3,4,5, to distinguish it from isoforms with a
different first exon. To date, four alternative splicing isoforms have
been identified: RCAN3-2,3,4b,5 (GenBank accession number:
AF176117), which presents an in-frame loss of 30 bases with
consequent absence of 10 amino acids in the middle of the
predicted protein [3]; RCAN3-2,5, lacking exons 3 and 4
(GenBank accession number: AY906854) [20]; RCAN3-2,4,5
(GenBank accession numbers: EF431960 and EF529733), lacking
exon 3; and RCAN3-2,3,5 (GenBank accession number:
EF467309), lacking exon 4 [22]. All identified isoforms were
expressed in the 7 investigated human tissues (heart, brain, small
intestine, lung, testis, prostate, and peripheral blood leukocytes),
with a constant expression prevalence of RCAN3-1,2,3,4,5 [22]. All
alternative protein isoforms interact with TNNI3, as demonstrated
by a glutathione-sepharose transferase fusion protein assay by
using the exon 2 encoded domain [20,22], while only RCAN3-
1,2,3,4,5, RCAN3-2,3,4b,5 and RCAN3-2,4,5 show the CIC
motif, necessary for calcineurin binding. In fact, RCAN3-2,5 and
RCAN3-2,3,5 show a frameshift in the exon 5-encoded amino acid
sequence, thus encoding for isoforms with different C-terminal
regions that lack the CIC motif, whose first five amino acids are
encoded by exon 4 and the remaining by exon 5 [22].
Since preliminary bioinformatic data revealed a not yet
investigated major complexity of the human RCAN3 locus, an
accurate multiple approach analysis of the locus was considered
necessary. Therefore, the aim of the present work is a combination
of in silico and in vitro analyses in order to explore as much as
possible the complexity of the human RCAN3 locus, focusing on
several new human RCAN3 spliced isoforms, on a new gene
overlapped and in antisense compared to RCAN3, as well as on
new RCAN3 isoforms with different 59 untranslated regions
(UTRs). Our combined data from this study indicate the presence
of a complex multi-transcript system at the RCAN3 locus.
Analysis of this locus and reverse transcription polymerase chain
reaction (RT-PCR) cloning experiments led us to identify 16 new
RCAN3 putative spliced isoforms, to be added to the five already
known. The new isoforms differ in both coding exons and non-coding
59UTR first exons. They were: RCAN3-1,3,4,5, RCAN3-1a,2,3,4,5,
RCAN3-1a,3,4,5, RCAN3-1b,2,3,4,5, RCAN3-1c,2,3,4,5, RCAN3-
1c,3,4,5, RCAN3-1,2,4, RCAN3-1a,2,4, RCAN3-1b,2,4, RCAN3-
1c,2,4,5, RCAN3-1,2,3,5, RCAN3-1a,2,3,5, RCAN3-1c,2,3,5, RCAN3-
1,2,5, RCAN3-1a,2,5 and RCAN3-1c,2,5. Bioinformatic analysis
allowed us also to identify the human RCAN3AS gene, the RCAN3
antisense gene, which in part overlaps with RCAN3-1a,2,3,4,5 on the
opposite strand. The 4 RCAN3AS isoforms (RCAN3AS-1,2,3,
RCAN3AS-1,2a,3,RCAN3AS-1,2b,3and RCAN3AS-1,3)d e n o m i n a t i o n
was assigned according to the HUGO Gene Nomenclature
Committee. Moreover, RT-PCR was performed in order to analyze
the expression patterns of RCAN3 alternative non-coding first exons
(1, 1c, 1a and 1b) and RCAN3AS-1,2,3mRNA isoformsin 17 different
human tissue types.
Furthermore, RCAN3 and RCAN3AS mRNA isoforms and
amino acid motif analyses were performed by mRNA and protein
multiple alignments, respectively. Since the evidence of alternative
59UTR first exons, analysis of RCAN3 and RCAN3AS genomic
sequences were conducted to predict possible different promoter
regions. Finally, genomic sequences were used to study alternative
donor and acceptor splice sequences and to compare the
evolutionary conservation of alternative non-coding first exon 1
or 1c - exon 2 junctions in different species.
Materials and Methods
Reverse transcription - Polymerase chain reaction
(RT-PCR)
Standard reverse transcription conditions were: 2 g total RNA,
Moloney murine leukaemia virus reverse-transcriptase (Promega,
Madison, WI; used with companion buffer) 400 U, oligo dT-15
2.5 mM, random hexamers 2 mM, dNTPs 500 mM each. RT
reaction was performed in a final volume of 50 mL for 60 min at
37uC. Standard PCR conditions for all amplifications were: 25 mL
final volume, primers 0.3 mM each, 12.5 mL BioMix Red (Bioline,
Taunton, MA); initial denaturation of 2 min at 94uC; 45 cycles of
30 s at 94uC, 30 s at the indicated annealing temperature (Ta),
30 s at 72uC; final extension of 7 min at 72uC. Deviations from
these conditions are given in details when appropriate.
RT-PCR cloning and plasmid construction
RT with standard conditions was used to obtain DNA
complementary to RNA (cDNA) from commercial human total
RNAs (Clontech, Palo Alto, CA). All used primers were designed
using Amplify software [25], following standard criteria [26].
Specific primers were used to clone RCAN3-1,2,3,4,5 (Table 1,
#1 and #2) cDNA from 5 mL of human peripheral blood
leukocytes cDNA using PCR standard conditions with a Ta of
61uC. Specific primers (Table 1, #3 and #4o r#2 as reverse
primers) were used to clone RCAN3-1a,2,3,4,5 cDNA from 3 mLo f
human prostate cDNA using PCR standard conditions, except
that there were 30 mL of final volume and 40 cycles with a Ta of
63uC. Specific primers (Table 1, #5 and #6o r#2 as reverse
primers) were used to clone RCAN3-1b,2,3,4,5 cDNA from 5 mLo f
human lung and testis cDNAs using PCR standard conditions with
aT a of 63uC. Primer #2, projecting on exon 5 of RCAN3 locus,
was used for RCAN3-1a,2,3,4,5 and RCAN3-1b,2,3,4,5 cloning, to
account for the possible incompleteness in 39 of the relative
expressed sequence tag (EST) reference sequences. Specific
primers (Table 1, #7 and #8) were used to clone RCAN3AS
cDNAs from 3 mL of human testis and pancreas cDNAs using
PCR standard conditions, except that there were 30 mL of final
volume and 35 cycles with a Ta of 61uC. To demonstrate the
possible presence of exon 1 in all identified RCAN3 isoforms to
date, 5 mL of human peripheral blood leukocytes cDNA was used
in a standard PCR with a Ta of 61uC. The data source for primers
design were the four GenBank RNA sequences previously
described by Facchin et al. 2008 [22] (RCAN3-2,3,4b,5 - GenBank
accession number: AF176117, RCAN3-2,5 - accession number:
AY906854, RCAN3-2,4,5 - accession numbers: EF431960 and
EF529733, and RCAN3-2,3,5 - accession number: EF467309) and
the RCAN3 reference sequence containing the non-coding exon 1
(GenBank accession number: NM_013441). To clone the RCAN3
alternative isoforms, a forward primer common to all gene
isoforms on exon 1 (Table 1, #1) and reverse primers specific for
RCAN3-2,3,4b,5, RCAN3-2,5, RCAN3-2,4,5 and RCAN3-2,3,5
isoforms (Table 1, #9, #10, #11, #12, respectively) were
designed. Each of these reverse primers presented two mismatches
in the last three bases of the 39 end (one being the 39-residue)
compared to the sequence of the other isoforms. Reverse primers
were designed encompassing specific exon - exon boundaries
(Table 1).
Moreover, in order to verify the possible presence of also exon
1a or exon 1b in all identified RCAN3 isoforms previously listed,
2 mL of human prostate and lung (for RCAN3-1a and RCAN3-1b
isoforms, respectively) cDNAs were used in PCR standard
conditions, except that 40 cycles with a Ta of 65uC were
performed, with exon 1a or 1b specific forward primers (Table 1,
Human RCAN3 Locus
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primers (Table 1, #9, #10, #11, #12).
RT-PCR products were gel-analyzed following standard
methods [27]. PCR products that revealed more than one band
on gel were first cloned in pCR2.1 plasmid by TA Cloning Kit
(Invitrogen, Carlsbad, CA, USA) and the obtained plasmids were
transformed in chemically competent TOP10 E. coli cells
(Invitrogen). To check the plasmid inserts sequences, PCR
products were obtained from 5 mL of a bacterial colony
resuspended in 50 mL of water under standard PCR conditions
(see subsection RT-PCR), except that there were 25 cycles with a
Ta of 58uC and using vector-specific forward and reverse primers
(Table 1, #13 and #14, respectively). These products were then
sequenced as described in below subsection, with the same primers
used for PCR.
To verify the existence of the RCAN3 isoforms lacking exon 2
(RCAN3-1,3,4,5, RCAN3-1c,3,4,5, RCAN3-1a,3,4,5 and RCAN3-
1b,3,4,5), four specific forward primers encompassing the bound-
ary between the alternative first exon (exons 1, 1c, 1a, 1b) and
exon 3 were designed (Table 1, #15, #16, #17 and #18,
respectively). In order to be isoform-specific, only five bases were
designed on the exon 3, while the most part of the primer (at least
18 bases) was complementary to the first alternative exon. These
forward primers were used with a common reverse primer
designed on exon 5 (Table 1, #2). To clone these RCAN3
isoforms cDNAs, PCR experiments were performed from 2.5 mL
of peripheral blood leukocytes cDNA (to clone RCAN3-1,3,4,5 and
RCAN3-1c,3,4,5), 2.5 mL of prostate cDNA (to clone RCAN3-
1a,3,4,5) and 5 mL of lung cDNA (to clone RCAN3-1b,3,4,5) using
PCR standard conditions, except that 40 cycles with a Ta of 63uC
were performed in a final volume of 25 mL.
59 RLM-RACE
59-RLM-RACE (Rapid Amplification of 59 cDNA end) was
performed using the FirstChoice RLM-RACE kit (Ambion,
Austin, TX) following the manufacturer’s instructions. Starting
from human prostate RNA (Clontech), cDNA to use in 59 RACE
reactions was obtained. 1 mL of prostate cDNA was used in first-
round 59 RACE reaction using the 59 Race Outer primer (#19)
and target gene-specific primer designed on RCAN3 exon 5 (#20).
PCR conditions for amplification were: 25 mL final volume,
primers 0.3 mM each, 12.5 mL BioMix Red (Bioline, Taunton,
MA); initial denaturation of 2 min at 94uC; 25 cycles of 30 s at
94uC, 30 s at 65uC, 120usa t7 2 uC; final extension of 7 min at
Table 1. Primer list.
No Primer sequence 59 R 39 gene or plasmid
c specificity
d
#1 CTCCCGTCCTGCGGCGGCGGGGCGT (F)
a RCAN3-1 exon 1/exon 1c
#2 CAGAGTCTCACCTATGCTGTTCG (R)
b RCAN3 isoforms exon 5
#3 GTGCTAGCTCCAGCTCAGCTACCT (F) RCAN3-1a exon 1a
#4 AGATAGGACTTGTCCCGCACTTCGC (R) (R) RCAN3-1a* exon 4
#5 GTATAACAGAAAAATGAACCAAGCACT (F) RCAN3-1b exon 1b
#6 CCATCATCTCATCCAAATCATCTTC (R) RCAN3-1b* exon 2
#7 GCGGCCGCAGGTAGCTGAGCTG (F) RCAN3AS exon 1
#8 ATGCTTTGTAGAAGTACTACAGGGA (R) RCAN3AS exon 3
#9 TGGGGCGGCAGGAGATAGGACTGTG (R) RCAN3-2,3,4b,5 exon 4b-exon 3
#10 TCCCGCGTGAAGTTCATATTTCTCTCCTTC (R) RCAN3-2,5 exon 5-exon 2
#11 CACTTCGCCGGACATCTGCACCTTC (R) RCAN3-2,4,5 exon 4-exon 2
#12 CGTGAAGTTCATATTTCTCTCCTGTGCAA (R) RCAN3-2,3,5 exon 5-exon 3
#13 AGGGTTTTCCCAGTCACGAC (F) pcR 2.1 plasmid
#14 CAGGAAACAGCTATGACCATGA (R) pcR 2.1 plasmid
#15 CGCCCGGCCTCTCCAGCAGGAAAG (F) RCAN3-1,3,4,5 exon 1-exon 3
#16 CGGCGGCGGGGCGTGCAGGAAAG (F) RCAN3-1c,3,4,5 exon 1c-exon 3
#17 TTGCCGGGAGGTGAACCGAGGAAAG (F) RCAN3-1a,3,4,5 exon 1a-exon 3
#18 GATTTCTGGCACGATAAATGAGAAAG (F) RCAN3-1b,3,4,5 exon 1b-exon 3
#19 GCTGATGGCGATGAATGAACACTG (F) 59 Race Outer
#20 TCACAGACATGAACCACCACGCTG (R) RCAN3 isoforms exon 5
#21 CGCGGATCCGAACACTGCGTTTGCTGGCTTTGATG (F) 59 Race Inner
#22 TGTCGACTCTGTTCCCGCGTGAAG (R) RCAN3 isoforms exon 5
#23 CTTCGCCGGACATCTGCACCTGTGCAA (R) RCAN3-1b* exon 4-exon 3
#24 TGCGGCGGCGGGGCGTGCAGGTGAG (F) RCAN3-1 exon 1
#25 GTCCTGCGGCGGCGGGGCGTGCAGTGG (F) RCAN3-1c exon 1c-exon 2
#26 GCTACACAGATCTGACTGGCTATCATTC (R) RCAN3-1/1c* exon 2
aF, forward primer.
bR, reverse primer.
cRCAN3-1: isoforms with exon 1; RCAN3-1a: isoforms with exon 1a; RCAN3-1b: isoforms with exon 1b; RCAN3AS: all RCAN3AS isoforms;
*: star indicates reverse primers used for specific alternative first exon isoforms cloning, but useful to clone all isoforms containing exon 2 or exon3o re x o n4 .
dWhen two exon numbers are provided, the primer encompasses the boundary between the two exons.
doi:10.1371/journal.pone.0024508.t001
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round reaction and internal primers (59 Race Inner primer #21
and gene-specific nested #22) with cycling as above. 10 mLo f
PCR products were gel-analyzed following standard methods [27],
were cloned using the TA Cloning kit and sequenced as described
in the following subsection.
DNA sequencing and sequence analysis
All sequences were determined using the Big Dye Terminator
Cycle Sequencing-Ready Reaction kit and automated DNA
sequence analyzer ABI-PRISM 3730 (Applied Biosystems, Foster
City, CA, USA). Sequences were analyzed by BLAST (Basic Local
Alignment Search Tool) family programs - accessed via the NCBI
(National Center for Biotechnology Information) homepage
(http://www.ncbi.nlm.nih.gov/) [28] - with default parameters,
using the following GenBank divisions: ‘‘nr’’ (non redundant) and
‘‘human ESTs’’ database sequences, in September 2010. Each
new isoform was sequenced twice using two independent
amplification reaction products as template.
RT-PCR expression analysis
Commercial total RNAs (Clontech) obtained from 17 adult
human whole normal tissues were used to clone RCAN3-1a,2,3,4,5,
RCAN3-1b,2,3,4,5 and RCAN3AS isoform cDNAs and to analyze
their different tissue expression profile: brain (pooled from 2 male
Caucasians), prostate (pooled from 16 male Caucasians), peripheral
blood leukocytes (pooled from 13 male/female Caucasians), thymus
(pooled from 2 male Caucasians), spleen (pooled from 13 male/
female Caucasians), stomach (pooled from 50 male Caucasians),
colon (pooled from 23 female Caucasians), bone marrow (pooled
from 3 male Asians), testis (pooled from 45 Caucasians), lung
(pooled from 3 male/female Caucasians), small intestine (pooled
from 2 male/female Caucasians), adrenal gland (pooled from 62
male/female Caucasians), mammary gland (pooled from 27 female
Caucasians), liver (from a 51-year old male Caucasian), pancreas
(pooled from 35 male Caucasians), heart (pooled from 10 male/
female Caucasians) and skeletal muscle (pooled from 7 male/female
Caucasians). To clone RCAN3-1a,2,3,4,5, RCAN3-1b,2,3,4,5 and
RCAN3AS isoforms primers #3 and #4, #5 and #23, #7 and #8
(Table 1) were used, respectively, and PCR reactions were
performed as described in the ‘‘RT-PCR cloning and plasmid
construction’’ subsection, except for RCAN3-1a,2,3,4,5 PCR that
was performed with 32 cycles. Reverse primer #23 was designed
overlapping specific exon 4 - exon 3 boundaries. The same tissues
were used to clone exon 1 - exon 2 and exon 1c - exon 2 junction
cDNAsfrom 3 mLofhumancDNAsusing the forwardprimers#24
and #25 (Table 1), respectively, and a common reverse primer
designed on exon 2 (#26, Table 1). Primer #24 was designed to be
specific for the exon 1, while primer #25 was designed
encompassing specific exon 1c - exon 2 boundaries. PCR was
performed in standard conditions, except that there were 35 cycles
with a Ta of 63uC. All five PCRs were qualitative, but they were
performed at the maximum distance from the PCR reaction
plateau, that is at the lowest cycle number where the product was
shown. Tissues choice was driven by the need to investigate the
largest panel of tissues and by the availability of human commercial
RNA in our laboratory.
Bioinformatic analysis of mRNA and protein isoforms
The nr/nt, refseq_rna and EST databases at NCBI were
searched by BLASTN software (default parameters, with no filter)
for the presence of any sequence relating to the alternative RCAN3
and RCAN3AS mRNA isoforms. The search was performed in all
organisms. In order to do this, for all human RCAN3 isoforms an
alternative first exon - exon 2 or alternative first exon - exon 3
query sequence was built to demonstrate the different use of the
alternative first exons: 1 or 1c or 1a or 1b. A following manual
analysis of the found sequences allowed us to attribute them with
high probability to a specific isoform. Then refseq_genomic and
other genomic sequence databases at NCBI [‘‘NCBI genomes’’,
‘‘High throughput genomic sequences (HTGS)’’, ‘‘Genomic
survey sequences (gss)’’ and ‘‘Whole-genome shotgun reads
(wgs)’’] were searched by BLASTN (default parameters, with no
filter, excluding Homo sapiens) for the presence of any sequence
relating to human alternative first exons - exon 2 or alternative first
exons - exon 3 junctions. ECgene Browser (http://genome.ewha.
ac.kr/ECgene/) [29] and Genome Browser at UCSC (http://
genome.ucsc.edu/cgi-bin/hgGateway) [30] were searched for the
presence of any sequence relating to the studied human RCAN3
and RCAN3AS mRNA isoforms. The analysis was carried out in
September 2010. Multiple alignment analysis of RCAN3 protein
isoforms, RCAN3 and RCAN3AS isoform mRNA sequences were
performed using ClustalW 1.83 software (http://www.ebi.ac.uk/
clustalw) [31]. BLASTP software (default parameters, with no
filter) was used to search for domain similarity.
The genomic organization of human RCAN3 isoforms with
alternative first exons and of human RCAN3AS isoforms were
studied to compare splice donor and acceptor sequences with the
consensus splice reference sequences [32]. The analysis was
carried out for different RCAN3 isoforms aligning alternative exons
1 - first intron - exon 2 or 3 (according to the considered isoform).
The same study was performed comparing first exon - first intron -
alternative exons 2 or 3 for RCAN3AS gene isoforms.
Finally, search of putative promoter regions by analysis of the
genomic sequences upstream 59 ends of the alternative first exons
of RCAN3 and RCAN3AS was performed by using the Neural
Network Promoter Prediction version 2.2 of Berkeley Drosophila
Genome Project (http://www.fruitfly.org/seq_tools/Promoter.
html) [33], the Neural Network Promoter Prediction Server
of BIOSINO (Bioinformation Center of Shanghai Institutes
for Biological Science Chinese Academy of Sciences, http://
Promoter.biosino.org) [34] and the First Exon Finder software
(http://rulai.cshl.org/tools/FirstEF/) [35]. Manual adjustment
was added to carry out promoter analysis.
Comparative sequence analysis between RCAN3-1,2,3,4,5
and RCAN3-1c,2,3,4,5 in all organisms
The nr/nt databases at NCBI were searched with BLASTN
and/or TBLASTN software (default parameters, with no filter,
excluding Homo sapiens) for the presence of any sequence relating to
human RCAN3-1,2,3,4,5 mRNA (NM_013441) and relative
protein (NP_038469), which were used as initial query sequences
to retrieve other organism transcripts.
For different species, more complete retrieved transcript
sequences were used as reference to query refseq_genomic and
other genomic sequence databases at NCBI [‘‘NCBI genomes’’,
‘‘High throughput genomic sequences (HTGS)’’, ‘‘Genomic survey
sequences (gss)’’ and ‘‘Whole-genome shotgun reads (wgs)’’] by
BLASTN software (default parameters, with no filter, excluding
Homosapiens). Inordertoanalyzethe conservation ofexon 1 - exon 2
and exon 1c - exon 2 sequences, the exon 1 - first intron - exon 2
and/or exon 1c - first intron - exon 2 sequences were annotated on
the species-specific reference genomic sequences. In some cases,
when the retrieved reference transcript sequences were incomplete
and did not match exon 1 or 1c, the attribution of the identified
transcripts to the RCAN3 isoform containing alternative exon 1 or
exon 1c was made, after a comparison between genomic sequence
of studied species and reference transcript sequence of an
Human RCAN3 Locus
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putative species-specific exon 1 - exon 2 or exon 1c - exon 2
sequences (Homo sapiens transcript used for Macaca mulatta, Macaca
mulatta transcript used for Callithrix jacchus, Canis lupus familiaris
transcript used for Ailuropoda melanoleuca and Mus musculus transcript
used for Rattus norvegicus assembly). Alignments between species-
specific alternative exon 1 and/or 1c - first intron - exon 2 were
performedinorder tocompare splicedonorand acceptor sequences
with the consensus splice reference sequences.
Finally, the reconstructed species-specific assembly was used as
query to search, with BLASTN, the specific organism ESTs in
order to prove the expression of the relative isoforms and to
possibly complete the 59 end transcript sequence.
Accession numbers
The nucleotide sequences of identified cDNAs have been deposited
in GenBank (http://www.ncbi.nlm.nih.gov/Genbank/) [36] under
the following accession nos.: RCAN3-1c,2,3,4,5 (HQ317426);R C A N 3 -
1,3,4,5 (HQ287726); RCAN3-1c,3,4,5 (HQ317427); RCAN3-1c,2,4,5
(JN203053); RCAN3-1a,2,3,4,5 (HQ317421 and JN228252, partial
coding sequence); RCAN3-1a,3,4,5 (HQ317422); RCAN3-1b,2,3,4,5
(HQ317423); RCAN3-1b,2 (HQ317445 and HQ317446, partial
coding sequence); RCAN3AS-1,2,3 (HQ317447 and HQ317448);
RCAN3AS-1,3 (HQ317425), RCAN3AS-1,2a,3 (HQ317424) and RCA-
N3AS-1,2b,3 (HQ419072).
Results
RCAN3 isoforms cloning and expression analysis
A combination of in silico and in vitro studies revealed several
spliced RCAN3 isoforms described below. According to the
nomenclature proposed by Davies and colleagues [4], RCAN3
mRNA isoforms are named RCAN3- followed by the hitherto
identified exon numbers (Figure 1). The same criteria were
adopted for the nomenclature of the new Homo sapiens gene
(RCAN3AS - RCAN3 antisense), identified here for the first time,
overlapped and on the opposite strand when compared with
RCAN3. To give a structure as clear as possible of the ‘‘Results’’
section, the first three subsections below, will be identified with the
name of the RCAN3 alternative first exon that is maintained in all
the isoforms described in the relative subsection. A separate
subsection will be presented for RCAN3AS.
RCAN3 exon 1a
The hypothesis of the existence of an alternative exon 1 (named
exon 1a) originated from the bioinformatic study of the RCAN3 locus.
A human EST sequence (GenBank accession number: BP326714,
human prostate tissue source) revealed an alternative exon 1 for
RCAN3, located on the reference genomic sequence (GenBank
accession number: AL034582) 434 base pair (bp) upstream of exon 1
of the reference RCAN3-1,2,3,4,5 isoform (NM_013441).
Therefore, a first pair of primers (#3 and #4, Table 1) was
designed on the most external sequence of the #BP326714 EST.
Sequence analysis of the RT-PCR product demonstrated the
existence of an mRNA sequence in human prostate (RCAN3-
1a,2,3,4, GenBank accession number: GQ411200), as reported
and discussed in our recent paper [19]. A new reverse primer (# 2,
Table 1) was then designed on the exon 5, in order to elongate the
sequence. Gel analysis revealed more than one PCR product
(Figure 2A) and sequence analysis showed the existence of two new
alternative RCAN3 isoforms: the expected new longer spliced
sequence RCAN3-1a,2,3,4,5 (GenBank accession number:
HQ317421) and a spliced alternative isoform lacking exon 2,
named RCAN3-1a,3,4,5 (GenBank accession number: HQ317422).
Sequence analyses also revealed the presence of possible RT-PCR
artifacts, due to the presence of distant sequence repetition, which
might induce a tridimensional RNA structure formation that
prevents the normal RT-PCR process [37]. The existence of the
RCAN3-1a,3,4,5 transcript was confirmed by an RT-PCR
amplification using RCAN3 isoform specific primers (#17 and
#2, Table 1). RCAN3-1a,2,3,4,5 gene comprises five exons, with
the alternative first exon (exon 1a) (Figure 1). Moreover, RT-PCR
performed with RCAN3-1a isoform specific forward and reverse
primers demonstrated the existence of three additional transcripts
(RCAN3-1a,2,4, RCAN3-1a,2,5, RCAN3-1a,2,3,5), which were not
revealed by the sequence analyses described above (Figure 1).
RACE assay revealed the existence of an RCAN3-1a,2,3,4,5
transcript (GenBank accession number: JN228252, Figure 1) with
additional 19 bp at the 59 end, compared with the RCAN3-
1a,2,3,4,5 sequence previously deposited (#HQ317421). In addi-
tion, the obtained 59 end is coherent with the reference EST
sequence (#BP326714), compared to which lacks the first 5 bp and
identifies a real TSS (transcription start site) of the RCAN3-
1a,2,3,4,5 transcript, within a putative transcription start region.
An expression panel of RCAN3-1a,2,3,4,5 cDNAs was obtained
by RT-PCR (primer #3 and #4, Table 1) from total RNAs
extracted from 17 adult human whole normal tissues (see ‘‘RT-
PCR expression analysis’’ subsection for tissues choice, data not
shown). In all tissues, gel electrophoresis analysis revealed the
expected size band referred to RCAN3-1a,2,3,4,5. Occasionally,
two other products of unexpected size were observed, one of which
is referred to the RCAN3-1a,3,4,5 spliced isoform. RCAN3-
1a,2,3,4,5 seems to be clearly expressed in prostate tissue, in
agreement with the reference EST source.
RCAN3 exon 1b
The hypothesis of the existence of exon 1b also originated from
the bioinformatic study of the RCAN3 locus. A human EST
sequence (GenBank accession number: CD700433, human naso-
pharynx tissue source) revealed an alternative exon 1 for RCAN3,
located on the reference genomic sequence (#AL034582) 4,443 bp
downstream of exon 1 of the reference RCAN3 isoform
(#NM_013441). Therefore, two primers (#5 and #6, Table 1)
were designed on the most external sequence of the #CD700433
EST. Sequence analysis of the RT-PCR product demonstrated the
existenceofanmRNAsequenceinhumanlung and testis(GenBank
accession numbers: HQ317445 and HQ317446, respectively),
matching the exon - exon junction between the new exon 1b and
the exon 2 of RCAN3. The reverse primer # 2 (Table 1), designed
on exon 5, was used to elongate the sequence. Thus, a new longer
sequence was cloned in lung tissue (GenBank accession number:
HQ317423) (Figure 2B). RCAN3-1b,2,3,4,5 mRNA consists of five
exons, where the first one (exon 1b) is alternative to exon 1 of
RCAN3-1,2,3,4,5 (Figure 1). Sequence analysis of PCR products
revealed the existence of other sequences due to RT-PCR artifacts
as previously discussed for RCAN3-1a,2,3,4,5 [37]. To verify the
RCAN3-1b,3,4,5 transcript absence an RT-PCR amplification with
isoform specificprimers(#18and#2,Table1)wasperformed,thus
confirming previous results, unlike what was observed for the other
isoforms lacking exon 2 with alternative first exons 1, 1c and 1a.
Moreover, RT-PCR performed with RCAN3-1b isoform specific
forward and reverse primers demonstrated the existence of one
additional transcript (RCAN3-1b,2,4), which was not revealed by the
sequence analyses described above (Figure 1).
With regard to RCAN3-1a,2,3,4,5, an expression panel of the
same 17 normal human tissues (see ‘‘RT-PCR expression analysis’’
subsection for tissues choice, data not shown) was obtained for
RCAN3-1b,2,3,4,5 (primers #5 and #23). In all tissues, gel
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Expression appears to be very low in many tissues, except for lung
where it is more evident.
RCAN3 exon 1 and exon 1c
Exon 1 is referred to the exon of reference for the RCAN3
isoform (#NM_013441), while exon 1c is a new exon identified
Figure 1. Schematic representation of RCAN3 gene locus: RCAN3 and RCAN3AS isoforms exon-intron organization. In the DNA scheme,
intron sizes (represented not in scale) in base pair (bp) are indicated between the two exons; exon sizes are represented in scale, except for exon -1 (that
overlaps withexon1a on the opposite strand)and exon1c (that lacksthe last 33bp of exon1). Exons 1, 2 and 3are located on the opposite strand. Exons 1and
5 may not appear in full length in the mRNA diagram due to incompleteness of sequence determination in 59 or 39.T h ed i a g r a m ,r e p r e s enting mRNAs, shows
the longest sequences available to date (see GenBank accession numbers in the figure). In the sense transcripts the direction of translation is to the right and in
the antisense transcripts it is to the left. ‘‘ ’’ indicates the DNA region comprised between 24,828,218 and 24,834,337 nucleotides of the chromosome 1
reference sequence NC_000001: it corresponds to the sequence showed in Figure 5A (see Figure 5A legend).
1 described in Strippoli et al., 2000,
2 described in Strausberg et al., 2002,
3 described in Canaider et al., 2006 and
4 described in Facchin et al., 2008.
‘‘*’’ indicates transcripts for which it was not possible to deposit a relative GenBank file. ‘‘N’’ indicates transcripts with exon 1c. ‘‘Q’’ indicates the start codon.
doi:10.1371/journal.pone.0024508.g001
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corresponds to the exon 1 lacking the last 33 bp.
RT-PCR (using primers #1 and #2) was performed on human
peripheralblood leukocytes cDNA to obtainRCAN3 cDNA inorder
to identify new alternatively spliced RCAN3 isoforms and to 59
elongate previously identified RCAN3 isoforms (RCAN3-2,3,4b,5,
RCAN3-2,4,5, RCAN3-2,3,5 and RCAN3-2,5), assuming the pres-
ence of reference exon 1 (Figure 1). Gel analysis revealed more than
one PCR product. In fact, RT-PCR products unexpectedly proved
to contain three new RCAN3 spliced isoforms in addition to the
known full length RCAN3 cDNA (GenBank accession numbers:
NM_013441 and AF176116): RCAN3-1c,2,3,4,5 cDNA (GenBank
accession number: HQ317426), lacking the last 33 bp of exon 1,
RCAN3-1,3,4,5 cDNA (GenBank accession number: HQ287726),
lacking exon 2, and RCAN3-1c,3,4,5 cDNA (GenBank accession
number: HQ317427), lacking exon 2 and the last 33 bp of exon 1
(Figure 1). The existence of the RCAN3-1,3,4,5 and RCAN3-1c,3,4,5
isoforms were confirmed by RT-PCR amplification using RCAN3
specific forwardprimers (Table 1,#15 and #16,respectively) and a
common reverse primer (#2, Table 1).
Sequence analysis did not reveal any sequence relating to the
four previously identified RCAN3 isoforms. Only one product
relating to exon 2 - exon 4 - exon 5 and containing the exon 1c
was retrieved (Figure 1). The presence of an EST corresponding to
this exon - exon junction (#CT001954) confirmed the existence of
the RCAN3-1c,2,4,5 isoform. Due to the presence of two nucleotide
variants in our product, with respect to the EST and genomic
sequences, and the impossibility to refer them to known SNP
(single nucleotide polymorphism) clusters, we submitted a
corresponding GenBank file (GenBank accession number:
JN203053, Figure 1) whose sequence presents two ‘‘N’’ (76 and
331 nucleotide positions), in order to indicate the difficulty to
identify with certainty the corresponding nucleotides.
Further specific reverse primers (Table 1: #9, #10, #11, #12)
were designed to demonstrate the presence of exon 1 in the RCAN3-
2,3,4b,5, RCAN3-2,5, RCAN3-2,4,5 and RCAN3-2,3,5 isoforms.
In all RT-PCR, gel analysis revealed two PCR products
(Figure 2C). Sequence analysis revealed that they corresponded to
the isoforms RCAN3-1,2,4 and RCAN3-1c,2,4, RCAN3-1,2,3,5 and
RCAN3-1c,2,3,5 or RCAN3-1,2,5 and RCAN3-1c,2,5 (Figure 1).
Since the reverse primers were designed encompassing specific
exon - exon boundaries and having to remove the primer sequence
from the cloned sequence, we could not deposit the corresponding
GenBank files. Sequence analysis of RCAN3-2,3,4b,5 RT-PCR
products revealed the presence of many nucleotide variants, which
did not allow us to refer them to specific isoforms.
Further primer pairs were designed to verify the expression of
all isoforms containing exon 1 - exon 2 junction (#24 and #26,
Table 1) and of all isoforms containing exon 1c - exon 2 junction
(#25 and #26, Table 1) in 17 normal human tissues (see ‘‘RT-
PCR expression analysis’’ subsection). In all cases, gel electropho-
resis analysis revealed one product of the expected size for all
analyzed tissues. Since the same expression pattern is evident
(Figure 3A and B), it is conceivable that the alternative use of exon
1 or exon 1c is stochastic [38].
RCAN3AS
Since the bioinformatic analysis revealed one EST (GenBank
accession number: BF448186) on the complementary strand and
overlapping RCAN3, primers (#7 and #8, Table 1) were designed
to amplify this cDNA from testis and pancreas RNAs. RT-PCR
products revealed more than one band on agarose gel. All PCR
products were cloned in pCR2.1 plasmid and the sequences of
several transformed clones were determined. Four different
isoforms were identified (Figure 4A) and their denomination has
recently been approved by the HUGO Gene Nomenclature
Figure 2. RCAN3-1a,2,3,4,5 and RCAN3-1b,2,3,4,5 cDNAs (example gel). A) 1% agarose gel loaded with human prostate tissue RT-PCR products.
Lanes 1 and 2: RCAN3-1a,2,3,4,5 (expected band size: 1,001 bp). The lowest band referred to the RCAN3-1a,3,4,5 isoform (band size: 747 bp). M: size
marker GeneRuler (500 ng). B) 1% agarose gel loaded with human lung tissue RT-PCR products. Lanes 1 and 2: RCAN3-1b,2,3,4,5 (expected band size:
1,050 bp); lane 3: beta 2 microglobulin (B2M, expected band size: 586 bp). M: size marker GeneRuler (500 ng). Other bands than the expected and not
indicated are referred to RT-PCR artifacts or to RCAN3-1a,2,4, RCAN3-1a,2,5, RCAN3-1a,2,3,5 (Figure 2A) and RCAN3-1b,2,4 (Figure 2B) transcript
assemblies whose existences were demonstrated by RT-PCRs performed with specific primers, as described in the text. C) 1% agarose gel loaded with
human peripheral blood leucocytes RT-PCR products. Lane 1: RCAN3-1,2,3,5 (expected band size: 511 bp) and RCAN3-1c,2,3,5 (unexpected band size:
478 bp); lane 2: RCAN3-1,2,5 (expected band size: 342 bp) and RCAN3-1c,2,5 (unexpected band size: 309 bp); lane 3: RCAN3-1,2,4 (expected band size:
337 bp) and RCAN3-1c,2,4 (unexpected band size: 304 bp). M: size marker GeneRuler (500 ng).
doi:10.1371/journal.pone.0024508.g002
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RT-PCR products: exon 1 - exon 2 junction cDNA in A and exon 1c - exon 2 junction cDNA in B (expected band size: 166 bp and 137 bp, respectively).
Lanes: 1, brain; 2, prostate; 3, peripheral blood leukocytes; 4, thymus; 5, spleen; 6, stomach; 7, colon; 8, bone marrow; 9, testis; 10, lung; 11, small
intestine; 12, adrenal gland; 13, mammary gland; 14, liver; 15, pancreas; 16, heart; 17, skeletal muscle. M: size marker GeneRuler (500 ng), lane 18: B2M
(expected band height: 586 bp) in peripheral blood leukocytes; lane 19: negative control.
doi:10.1371/journal.pone.0024508.g003
Figure 4. RCAN3AS mRNA isoforms sequence identification and analysis. A) 1% agarose gel loaded with RCAN3AS colony PCR products.
From left to right: RCAN3AS-1,3 (expected band size: 547 bp), RCAN3AS-1,2a,3 (expected band size: 658 bp), RCAN3AS-1,2b,3 (expected band size: 699
bp) and RCAN3AS-1,2,3 (expected band size: 606 bp). M: size marker GeneRuler (500 ng). Band heights result by using specific pCR2.1 plasmid primer
pairs. B) RCAN3AS mRNA isoform sequences aligned by ClustalW software. Exon 2a and exon 2b are longer than exon 2 in their 59 (52 bp and 93 bp,
respectively).
doi:10.1371/journal.pone.0024508.g004
Human RCAN3 Locus
PLoS ONE | www.plosone.org 8 September 2011 | Volume 6 | Issue 9 | e24508Committee. RCAN3AS name indicates that this gene is on the
opposite strand compared to RCAN3 and RCAN3AS isoforms were
named on the basis of the exon organization. We considered
RCAN3AS-1,2,3 (GenBank accession numbers: HQ317447 - testis
and HQ317448 - pancreas, respectively) as reference isoform since
it matches the #BF448186 EST. It consists of 3 exons, it is located
on the RCAN3 locus (1p36.11) and it is on the opposite strand of
RCAN3 (Figure 1). Moreover, RCAN3AS-1,2,3 overlaps with the
first 32 bases of the RCAN3 exon 1a, according to the two
corresponding EST sequences.
The other three unexpected RCAN3AS isoforms have been
cloned by RT-PCR in human pancreas: RCAN3AS-1,2a,3
(GenBank accession number: HQ317424), RCAN3-1,2b,3 (Gen-
Bank accession number: HQ419072) and RCAN3AS-1,3 (GenBank
accession number: HQ317425) (Figure 1). RCAN3AS-1,2a,3 and
RCAN3AS-1,2b,3 consist of 3 exons, with an elongation of 52 bp
and of 93 bp of the exon 2 (in 59), respectively, compared with
exon 2 of RCAN3AS-1,2,3 (Figure 4A and B). RCAN3AS-1,3
consists of 2 exons, since it lacks exon 2 completely, compared with
the RCAN3AS-1,2,3 reference sequence (Figure 4A and B).
To obtain preliminary information about RCAN3AS-1,2,3
expression, RT-PCR with primers #7a n d#8 (Table 1) was
performed in 17 adult human whole normal tissues (see ‘‘RT-
PCR expression analysis’’ subsection for tissues choice, data not
shown). In all cases, gel electrophoresis analysis revealed the
presence of the expected size band referred to RCAN3AS-1,2,3,
which is present in all investigated tissues and in the same
conditions of amplifications it seems to be more expressed in testis
and pancreas.
Bioinformatic analysis of RCAN3 mRNA isoforms
To verify if alternative RCAN3 isoforms were present in human
sequence databases, a search at NCBI databases was performed by
BLASTN software.
Human EST sequences matching alternative first exon - exon 2
junction were identified and assigned to a specific isoform after
manual analysis of the retrieved sequences. Human EST
sequences matching alternative first exon - exon 3 junction were
not identified. Detailed summary of results obtained by this
bioinformatic analysis is described in Table 2. Many ESTs
extending from exon 2 to subsequent exons were found, but due to
the high complexity of the RCAN3 locus, they could be assigned to
any isoform containing these exons and any alternative first exon
and they were not compared in Table 2.
The same results were obtained using the ECgene Browser and
the UCSC Genome Browser. These two independent browsers
showed another alternative isoform (GenBank accession number:
BU947377), which was not further analyzed in the present work.
BU947377 EST showed exons 3-4-5 linked to a new alternative
exon 2. Moreover, an analysis of newly identified RCAN3 mRNA
sequences was performed. Three different SNPs for the RCAN3
mRNA isoform have been reported in the single nucleotide
polymorphism database (dbSNP) at the NCBI (http://www.ncbi.
nlm.nih.gov/entrez/query.fcgi?db=snp) [39] as clusters rs196429
(average heterozygosity 6 standard error: 0.42860.175), rs196430
and rs196432 (average heterozygosity 6 standard error:
0.49760.040), as discussed by Facchin et al. [22]. The first two
SNPs were found in exon 4, while the third was found in exon 5
(nucleotide positions 727 bp, 775 bp and 976 bp, respectively,
Table 2. RCAN3 cDNA isoforms in Homo sapiens databases.
cDNA Homo sapiens
a nr/nt or ref_seq Homo sapiens EST EST tissue or cells
RCAN3-1,2,3,4,5 NM_013441 BC035854 BM928218 Brain
CR986931 Uncharacterized tissue
DN991656 Brain
BU180267 Pancreas
BU157485 Pancreas
BQ894646 Pancreas
BQ687884 Pancreas
BQ686955 Pancreas
RCAN3-1,2,4,5 None BM808737 Hippocampus
RCAN3-1,3,4,5 None None
RCAN3-1a,2,3,4,5 GQ411200 BP326714 Prostate
AW408648l Lymph, germinal center B cells
RCAN3-1a,3,4,5 None None
RCAN3-1b,2,3,4,5 None CD700433 Nasopharynx
RCAN3-1c,2,3,4,5 None BQ929181 Prostate
CX752875 Cell line derived from blastocyst
BX642220* Not declared
RCAN3-1c,2,4,5 None CT001954 T-Lymphocytes
RCAN3-1c,3,4,5 None None
Search was performed with BLASTN software (default parameters, with no filter).
Alternative first exon - exon 2 or 3 query sequences were used. Manual analysis of entire found sequences allowed us to assign them to a specific isoform.
aexcluding genomic sequences. ‘‘nr’’ (non redundant), ‘‘nt’’ (nucleotide), ‘‘ref_seq’’ (reference sequence) and ‘‘EST’’ (expressed sequence tag).
*This EST extends only up to exon 3.
doi:10.1371/journal.pone.0024508.t002
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presence of G or A in all three SNPs described does not change the
encoded amino acid sequence (amino acids 138 and 154 are
proline and 221 is threonine, respectively, referring to
NM_013441). In Table S1, the presence of G or A are reported
for all 6 newly identified RCAN3 isoforms (RCAN3-1,3,4,5, RCAN3-
1c,2,3,4,5, RCAN3-1c,3,4,5, RCAN3-1a,2,3,4,5, RCAN3-1a,3,4,5
and RCAN3-1b,2,3,4,5), on the basis of the retrieved nucleotide
in the corresponding position of our cloned isoforms (‘‘GenBank
accession no.’’, second column of Table S1). SNPs data referred to
previously described RCAN3 isoforms were discussed in Facchin
et al. [22].
Search by BLASTN software in nr/nt, refseq_rna and EST
databases at NCBI in all organisms (excluding Homo sapiens)
identified only sequences similar to human exon 1 - exon 2 and
human exon 1c - exon 2 junctions, which were assigned to
RCAN3-1,2,3,4,5 and RCAN3-1c,2,3,4,5 after manual analysis of
the entire sequences retrieved (Table S2). No defined or reference
sequence or EST transcript matching human exon 1 - exon 3,
exon 1a - exon 2, exon 1a - exon 3 or exon 1c - exon 3 junctions
were identified, except for one Sus scrofa EST sequence matching
human exon 1c - exon 3 (GenBank accession number:
BW970272). The BLASTN search performed using the human
alternative first exons - exon 2 or 3 sequences as query against all
the genomic databases, lead to the observation, in some organisms,
of the presence of sequences matching with human first exons
(Table S2 and Table S3), allowing us to speculate on the existence
of relative species-specific transcripts containing them.
Comparing splice donor sequences surrounding GT signal site
in the transition between alternative first exons and following first
intron with the consensus reference sequence (CAGGTRAGT,
where R is referred to a purine nucleotide – [32]), exon 1c donor
sequence results to be the more adherent. Splice donor sequences
of exon 1, 1a and 1b showed 1, 2 and 3 nucleotides substitution
(purine/purine or pyrimidine/pyrimidine), respectively, when
compared with the consensus sequence. Splice donor sequences
of exon 1 showed 2 nucleotide differences, while exon 1c and exon
1a showed one difference. Comparing splice acceptor sequences
surrounding AG signal site in the transition between alternative
first introns and exon 2 or 3 with the consensus reference sequence
(YACN, where Y is referred to pyrimidine nucleotide and N to any
nucleotide – [32]), all studied acceptor sequences were conserved
(Figure S1). In figure S1, the exon 1b - first intron - exon 3
sequence is not shown, since we have not retrieved a correspond-
ing mRNA.
RCAN3 promoter analysis
Promoter analysis in order to detect consensus promoter
sequences and hypothetical TSSs was performed on AL034582
as genomic reference sequence (Figure 5A).
Only one CpG island of 202 bp in length was found by First
Exon Finder software upstream exon 1 of RCAN3 gene, extending
from nucleotide (nt) 2,767 to nt 2,968 and with an high GC
percentage/content (GC 82%) (the RCAN3 mRNA begins at nt
2,970 and exon 1 ends at nt 3,223). Using the same software, no
CpG island was detected adjacent to exon 1a or exon 1b. Three
short sequences containing possible TSSs were identified by
Promoter Prediction tool (Berkeley Drosophila Genome Project)
and by Neural Network Promoter Prediction server within the
CpG island (2,832-2,836, 2,857-2,859 and 2,964–2,966 nt posi-
tions, according to exon 1 boundaries). Another short sequence
with TSSs was identified upstream the CpG island (2,742–
2,748 nt positions). The identified short sequence at 2,964–2,966
nucleotide positions is very close to the first nucleotide of the
NM_013441 reference transcript, assembled considering the
complete 59 RCAN3 sequence derived from a massive sequencing
project whose purpose was to clone full human ORFs (open
reading frames) from libraries enriched for full-length cDNAs [24].
Therefore, the identified sequence containing a possible TSS could
correspond to a real transcription start region.
First Exon Finder software detected a promoter region from nt
1,963 to nt 2,532, a region starting upstream of exon 1a and
ending within the same exon (the RCAN3-1a,2,3,4,5 mRNA begins
at nt 2,424 and its exon 1 ends at nt 2,536, according to BP326714
reference EST), whose possible TSS has been verified by RACE
method (as described in subsection ‘‘RCAN3 exon 1a’’). Moreover,
manual analysis of genomic sequence upstream exon 1a revealed a
guanine repetition responsible for G-quadruplex structure forma-
tion [40]. The regulated formation of these structures in the
promoter region has been demonstrated to provide an elegant
nucleic-acid-based mechanism for transcription modulation [41].
Four TSSs were also predicted upstream of exon 1b (from nt
7,640 to nt 7,801, according to CD700433 reference EST) at
5,674, 5,756, 6,671 and 7,028 nucleotide positions by Promoter
Prediction tool (Berkeley Drosophila Genome Project). However,
no TSS lied adjacent the known exon 1b start. Given the average
length of 210 bp of human genes 59UTR (18 bp and 2858 bp,
minimum and maximum 59UTR length, respectively) [42], only
the TSS located in position 7,028 may be plausible, also assuming
that exon 1b could extend upstream [42,43].
On the other hand, manual analysis of genomic sequence
(16 bp and 177 bp upstream, respectively) of exon 1b revealed a
possible ‘‘TATA box’’ (TAAA from nt 7,503 to nt 7,506) and a
‘‘CAAT box’’ (CAAT from nt 7,463 to nt 7,466), that no Promoter
Prediction software had identified. The distance between the two
sequence boxes is coherent.
RCAN3 protein isoforms
Figure 6 shows the alignment (performed by ClustalW software
and manually revised) of the 6 human RCAN3 protein isoform
sequences (RCAN3-2,3,4,5, RCAN3-2,4,5, RCAN3-2,3,4b,5,
RCAN3-2,3,5, RCAN3-2,5 and RCAN3-4,5). RCAN3-2,3,4,5
protein is referred to RCAN3-1,2,3,4,5, RCAN3-1a,2,3,4,5, RCAN3-
1b,2,3,4,5 and RCAN3-1c,2,3,4,5 mRNA products (RCAN3
reference protein, GenBank accession number: NP_038469). In
these mRNA isoforms the conserved coding sequence starts in
exon 2 and finishes in exon 5. RCAN3-2,4,5 refers with certainty
to RCAN3-1c,2,4,5 mRNA product, where frame is conserved in
junction between exons 2 and 4. RCAN3-4,5 is the product of
RCAN3-1,3,4,5, RCAN3-1a,3,4,5, and RCAN3-1c,3,4,5 mRNAs,
whose coding sequence starts in exon 4. Alignment analysis
highlights that the exon 2 encoded domain is the same in all the
alternative RCAN3 isoforms that contain it. The product of exon
2 has been shown to be sufficient for binding to TNNI3 [20]. All
the studied proteins, with the exception of RCAN3-2,3,5 and
RCAN3-2,5, contain the CIC motif, the calcineurin binding site
[7]. Due to the out-of-frame joining between exons 3 and 5 and
between exons 2 and 5, the carboxyl terminus sequence encoded
by RCAN3-2,3,5 and by RCAN3-2,5 cDNAs is not similar to that of
the RCAN3 product sequence, as previously reported by us [22].
All these protein sequences do not present similarities with any
other human putative domain as searched by the BLASTP
software (default parameters, with no filter).
Comparative sequence analysis in all organisms
NM_013441 (human RCAN3-1,2,3,4,5 gene) and NP_038469
(human RCAN3-1,2,3,4,5 protein) were used as initial query
sequences to retrieve all transcripts relative to other organisms by
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regard to RCAN3-1,2,3,4,5, transcript models were found only in
primates. On the contrary, transcribed sequences and transcript
models referred to RCAN3-1c,2,3,4,5 were found in primates,
mammals - not primates, and not mammals (Table S3, second
column). For all identified transcripts, the corresponding reference
genomic sequences were retrieved (Table S3, third column). The
analyses described in this paper allowed us to observe more transcript
sequences and relative genomes compared to those indicated in
Table S3 (retrieved sequences also for Equus caballus, Oryctolagus
cuniculus, Ornithorhynchus anatinus, Monodelphis domestica, Taeniopygia
guttata and Xenopus tropicalis). However, they were not reported
because incomplete and insufficient to rebuild exon1/1c - first intron
- exon 2 junctions. Figure S2 shows species-specific alignments
Figure 6. RCAN3 isoform predicted protein sequences aligned by ClustalW software. RCAN3-2,3,4,5 here refers to RCAN3-1,2,3,4,5, RCAN3-
1a,2,3,4,5, RCAN3-1b,2,3,4,5 and RCAN3-1c,2,3,4,5 mRNA products. RCAN3-2,4,5 refers with certainty to RCAN3-1c,2,4,5 mRNA product. In all these
isoforms the coding sequence starts in exon 2 and finishes in exon 5. RCAN3-4,5 refers to RCAN3-1,3,4,5, RCAN3-1a,3,4,5 and RCAN3-1c,3,4,5 product
sequences. In all these isoforms the coding sequence starts in exon 4. Due to the lack of exon 2, RCAN3-4,5 sequence is shorter than RCAN3-1,2,3,4,5
protein and lacking the amino terminus containing the exon 2 product necessary for human cardiac troponin I (TNNI3) binding. Due to out-of-frame
joining between exons 2 and 5 and between exons 3 and 5, the carboxyl terminus sequence encoded by RCAN3-2,5 and by RCAN3-2,3,5 cDNAs,
respectively, is not similar to that of RCAN3-1,2,3,4,5 product sequence. In bold and italic the initial methionine of the proteins. Black border box: exon
2 encoded amino acids; shaded dark grey residues: FLISPP motif. Shaded light grey: CIC motif, with the embedded ELHA motif (KYELHAGTESTPS). The
diagram shows the longest protein sequences available to date (see mRNA GenBank accession numbers in text or figure 1). Alignment was made by
ClustalW software and manual adjustment.
doi:10.1371/journal.pone.0024508.g006
Figure 5. Promoter analysis in RCAN3 alternative first exons and RCAN3AS isoforms. Highlighted in light grey: promoter region;
highlighted in dark grey: CpG island; in bold and underlined: exon sequence; in bold, italic and double underlined: GT splice signal; in bold, white and
highlighted in black: transcription start site (TSS). A) AL034582 genomic sequence from 1,801 to 7,920 nucleotides, corresponding to the
chromosome 1 reference sequence NC_000001 from 24,828,218 to 24,834,337 nucleotides, respectively. The same genomic interval is indicated by
two graphic symbols in the DNA scheme of Figure 1. In bold, white and highlighted in dark grey: guanine repetitions; in bold, white and highlighted
in light grey: ‘‘CAAT box’’ and ‘‘TATA box’’; - -: genomic interval. B) AL034582 reverse genomic sequence (1-1,360 bp corresponding to 3,700-2,341 bp
of AL034582 direct sequence) with RCAN3AS exon 1 (bold and underlined).
doi:10.1371/journal.pone.0024508.g005
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organisms, identified by bioinformatic search and following manual
adjustment. The study of the donor splicing sequences for all studied
genomic sequences showed the presence of high sequence conserva-
tion compared to human consensus sequence, especially when it is
referred to the exon 1c - exon 2 junction. Moreover, only in primates
(white block in Figure S2) both donor signal sites were present on
genomic sequences. The donor splice sequence related to exon 1c
showed an identity of 89% with consensus sequence, while the donor
splice sequence related to exon 1 showed an identity of 67%. The
conservation of both splice donor sequences suggests their alternative
possible use as it happens in Homo sapiens.I nm a m m a l s - n o tp r i m a t e s
(light grey block in Figure S2), the comparison of genomic sequences
showed high conservation of sequences compared to human genomic
sequences and only the donor splice site, corresponding to human
exon 1c, was retrieved (donor splice sequences showed identity of
100% with the consensus sequence, 9/9 bp). The splice donor site
related to human exon 1 was not present. Even in not mammal
organisms (Gallus gallus and Danio rerio), the analysis of genomic
sequences and the absence of transcribed sequences exon 1 - like
indicated that only the splice site similar to human exon 1c could be
used, whosesignal sequences are highly conserved (dark grey block in
Figure S2).
Finally, a species-specific exon 1 - exon 2 or exon 1c - exon 2
assembly were used as query to search by BLASTN the specific
organism ESTs, in order to prove the expression of the relative
isoforms and to complete the 59 end transcript sequence. No ESTs
related to the presence of human exon 1 - exon 2 junction were
identified. ESTs referred to exon 1c - exon 2 junction were
retrieved for Bos taurus, Sus scrofa, Canis lupus familiaris, Mus musculus,
Gallus gallus and Danio rerio (Table S3, fourth column).
Bioinformatic analysis of RCAN3AS mRNA isoforms
In order to verify if RCAN3AS isoforms were present in human
sequence databases, a search of NCBI databases was performed by
BLASTN software. For all RCAN3AS isoforms reference genomic
sequences were represented by the two contigs AL031431 and
AL034582. Table 3 resumed EST identified sequences and their
tissue source.
The same EST results were obtained for the four RCAN3AS
isoforms using the ECgene Browser and the UCSC Genome
Browser. These two independent browsers showed another
alternative isoform (GenBank accession number: BM457392),
which was not further analyzed in the present work. BM457392
was an expressed sequence on the opposite strand of RCAN3 and
had three exons. The third exon is overlapping but more extended
in 39 compared to RCAN3AS exon 3.
Search by BLASTN software in nr/nt, refseq_rna and EST
databases at NCBI in all organisms (excluding Homo sapiens) did not
identify sequences similar to human RCAN3AS isoforms.
Analysis of the splice donor sequence surrounding the GT
signal site in the transition between exon 1 and the first intron of
RCAN3AS isoforms with the consensus reference sequence
underlined a high similarity. Comparing specific splice acceptor
sequences surrounding the AG signal site in the transition
between first introns and alternative exons 2 (2, 2a, 2b) or exon 3
and the consensus reference sequence, we observed that all
studied acceptor sequences resulted very adherent, except for a
nucleotide difference in the first intron - exon 2a boundary
(Figure S3).
RCAN3AS promoter analysis
In order to detect consensus promoter sequences and a
hypothetical TSS, promoter analysis was performed by using
AL034582 as genomic reference sequence (Figure 5B). A window
of 6,000 bp upstream and 80 bp downstream RCAN3AS exon 1
was analysed with different tools. Firstly, the Exon Finder software
allowed us to identify a CpG island of 201 bp in length (GC,
81.5%) and a promoter region starting and ending, respectively,
622 bp and 52 bp upstream of the CpG island. Moreover, Neural
Network Promoter Prediction server of BIOSINO showed a
possible TSS in the first base downstream the identified CpG
island, located 371 bp upstream the exon 1 start (according to
BF448186 reference EST). This finding could suggest a 59
elongation of RCAN3AS exon 1, considering also that the
complementary strand in this portion results to be transcribed as
demonstrated by BP326714 EST (referred to RCAN3-1a,2,3,4,5
isoform, on the opposite strand).
Table 3. RCAN3AS cDNA isoforms in Homo sapiens.
cDNA Homo sapiens nr/nt or ref_seq Homo sapiens EST EST tissue
RCAN3AS-1,2,3 AL031431 AL034582 BF448186 Lung carcinoid
AW339253 Lung
BG149353* Lung carcinoid
AW339444* Lung carcinoid
AW134996* Lung carcinoid
AA992107* Testis
RCAN3AS-1,2a,3 AL031431 AL034582 BQ025862 Placenta
BE551182 Lung carcinoid
BE551149 Lung carcinoid
RCAN3AS-1,2b,3 AL031431 AL034582 CR741819 Testis
RCAN3AS-1,3 AL031431 AL034582 None None
Search was performed by BLASTN software (default parameters, with no filter).
‘‘nr’’ (non redundant), ‘‘nt’’ (nucleotide), ‘‘ref_seq’’ (reference sequence) and ‘‘EST’’ (expressed sequence tag).
*ESTs that could be referred to any RCAN3AS alternative exon 2 isoforms.
doi:10.1371/journal.pone.0024508.t003
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All four RCAN3AS isoforms have the same coding sequence
(171 bp) on exon 3 (Figure 4B) that encodes for a predicted protein
of 56 amino acids, with a theoretical pI/Mw of 4.70/6,356.42.
This protein sequence has been deposited in GenBank by Venter
et al. (2005), as a conceptual translation (#EAW95131).
By using BLASTP software, RCAN3AS sequence did not show
similarity with any known protein or protein domain.
Discussion
Human RCAN3 [3] is mapped on chromosome 1 and belongs to
the human RCAN gene family that includes RCAN1, mapping on
chromosome 21 [1], and RCAN2, mapping on chromosome 6 [2].
All three genes can be considered multi-transcript systems, because
of the amount of alternative isoforms described. The RCAN1 gene
consists of seven exons, amongst which exons 1-4 can be
alternatively transcribed or spliced, thus producing different
mRNA isoforms that encode for two major protein isoforms of
252 (RCAN1-1) [44] and 197 (RCAN1-4) amino acids [45,46].
RCAN2 consists of seven exons and produces three different
transcripts (RCAN2-1,3, RCAN2-2,3, and RCAN2-4) and two
related protein products (RCAN2-3 and RCAN2-4) [47]. RCAN3
is a five-exon gene [20,24] spanning 33,042 bp and encoding for a
241 amino acids protein (estimated molecular weight 27.5 kDa).
Five RCAN3 transcripts generated by alternative splicing have
been identified to date (Figure 1) [3,20,22], as described in the
Introduction section.
The denomination for RCAN genes (previously named DSCR1L
genes) has been widely discussed in an international forum
manuscript [4]. The name ‘‘Regulator of calcineurin’’ indicates
that all three family members interact with and regulate
calcineurin [5-7], a Ca
2+/calmodulin-activated serine/threonine
phosphatase that is involved in the transcriptional activation of
many target genes. RCAN3 binding to calcineurin is exclusively
mediated by a CIC motif, also present in RCAN1 and RCAN2.
The CIC motif contains the ELHA calcineurin-binding sequence,
which has been demonstrated to inhibit the NFAT-dependent
cytokine gene expression in human T cell lines and, therefore, T
cell activation [7,8]. RCAN3-2,3,4,5, RCAN3-2,3,4b,5 and
RCAN3-2,4,5 all contain the CIC motif, necessary for calcineurin
binding. However, RCAN3-2,5 and RCAN3-2,3,5 isoforms do
not include the functional CIC motif. It has been therefore
hypothesized that they do not interact with calcineurin [7,22].
With regard to the functional role of RCAN3, our group
demonstrated that it interacts with TNNI3 [20], the inhibitory
cardiac troponin preventing contraction in the absence of calcium
and troponin C [21]. Exon 2 has been found to be sufficient for the
binding of RCAN3 with TNNI3 [20]. Therefore, all alternative
protein isoforms to date identified interact with TNNI3 [20,22].
In the present work, a combination of in silico and in vitro
analyses allowed us to explore the complexity of the human
RCAN3 locus, focusing on new human spliced isoforms, a new
gene overlapping and in antisense with respect to RCAN3, and new
RCAN3 isoforms with different 59UTR, whose expression is
possibly regulated by alternative promoter sequences.
Here we describe 16 novel RCAN3 mRNA isoforms. Four new
isoforms were identified unexpectedly during RCAN3-1,2,3,4,5
RT-PCR cloning: RCAN3-1,3,4,5, lacking exon 2, RCAN3-
1c,2,3,4,5, lacking the last 33 bp of exon 1, RCAN3-1c,3,4,5,
lacking exon 2 and the last 33 bp of exon 1 and RCAN3-1c,2,4,5,
lacking exon 3 and the last 33 bp of exon 1 (Figure 1).
Furthermore new isoforms of RCAN3, carrying other alternative
first exons compared to the reference transcript RCAN3-1,2,3,4,5,
were identified by sequence comparison with EST database entries
and following search by Genome and EcGene Browsers. Two
isoforms, containing alternative exon 1a, localized 434 bp
upstream the reference exon 1, were cloned in human prostate
tissue: a new long sequence RCAN3-1a,2,3,4,5 and a spliced
alternative isoform lacking the exon 2, named RCAN3-1a,3,4,5
were found (Figure 1 and Figure 2A). The existence of the RCAN3-
1,3,4,5, RCAN3-1c,3,4,5 and RCAN3-1a,3,4,5 isoforms were also
confirmed by RT-PCR amplification using RCAN3 specific
forward primers and a common reverse primer. Moreover, a
new isoform containing exon 1b, 4,443 bp downstream the
reference exon 1, was identified in human lung and testis tissues
(Figure 1 and Figure 2B). All four identified alternative first exons
(1, 1c, 1a and 1b) are not coding and, in all isoforms containing the
following exon 2 - exon 3 - exon 4 - exon 5 assembly, the coding
sequence starts in exon 2, giving rise to the same protein product
of 241 amino acids (RCAN3-2,3,4,5). The protein maintains both
domains for TNNI3 binding and CIC motif to bind calcineurin
(Figure 6). Instead, the three new isoforms RCAN3-1,3,4,5,
RCAN3-1c,3,4,5 and RCAN3-1a,3,4,5 produce a protein product
of 116 amino acids that lacks the exon 2 encoded domain,
necessary for TNNI3 binding, while it maintains the CIC motif
(Figure 6).
In order to demonstrate the possible presence of exon 1 in the
previously identified isoforms RCAN3-2,4,5, RCAN3-2,3,5, RCAN3-
2,3,4b,5 and RCAN3-2,5, specific RT-PCR cloning experiments
were performed revealing the existence of the isoforms RCAN3-
1,2,4, RCAN3-1,2,3,5 and RCAN3-1,2,5, and of the unexpected
isoforms RCAN3-1c,2,4, RCAN3-1c,2,3,5 and RCAN3-1c,2,5
(Figure 1 and Figure 2C). Due to the specific isoform primer
design, these findings do not allow us to assert with certainty that
these alternative isoforms are referred to complete isoforms
(extended up to exon 5), although this event is likely. On the
other hand, the discovery of four alternative non-coding first exons
prompted us to also perform RT-PCR experiments with specific
forward and reverse primers, leading to the identification of
RCAN3-1a,2,4, RCAN3-1a,2,5, RCAN3-1a,2,3,5 and RCAN3-1b,2,4
additional transcript assemblies (Figure 1). This confirmed the
hypothesis that all the isoforms cloned and starting by exon 2
could be related to all the possible alternative first exons and not
only to the previously known reference exon 1.
RCAN3 locus complexity was enriched by the identification of
RCAN3AS gene, located on the opposite strand compared to
RCAN3 and partially overlapping RCAN3 exon 1a with its exon 1
(exon -1 in Figure 1). RCAN3AS-1,2,3 isoform is composed by
three exons and it has been cloned in human testis and pancreas
tissues. Other three RCAN3AS isoforms (RCAN3AS-1,2a,3, RCAN3-
1,2b,3 and RCAN3AS-1,3) have been cloned in human pancreas.
RCAN3AS-1,2a,3 and RCAN3AS-1,2b,3 consist of 3 exons, with an
exon 2 59 elongation of 52 bp and of 93 bp, respectively.
RCAN3AS-1,3 consists of 2 exons, since it lacks exon 2 completely
(Figure 1 and Figure 4). The predicted protein encoded is the same
for all RCAN3AS isoforms, since it is comprised in exon 3 and
consists of 56 amino acids. Its sequence has no similarity with any
human putative domain.
The comprehension of the genomic organization of RCAN3AS
here presented represents the basis to carry out further functional
studies in order to investigate its possible regulative role on
RCAN3, also as a putative non-coding RNA (ncRNA).
Our findings bear out possibility that gene expression regulation
in higher eukaryotes is enriched with the wide number of
alternative spliced isoforms, with data on overlapping sequences
(‘‘overlapping genes’’), sequences related to ncRNA and natural
antisense RNA (NAT), whose presence at a gene locus identify a
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all human genes and 74% of multiexon human genes are
alternatively spliced [49]. These estimates do not take into account
how many different alternatively spliced isoforms exist for any
given gene [49]. Different mechanisms of alternative splicing could
be identified in human genes, from lacking three bases from one
exon, like in subtle splicing [50,51], to lacking one or more discrete
exons [52], like in our cases. All these mechanisms probably
explain the functional complexity of vertebrates, as opposed to
invertebrates [52].
To seek confirmation of new RCAN3 and RCAN3AS isoforms
evidence and to retrieve information about their expression, EST
or defined cDNA (DNA complementary to RNA) sequences were
searched in all organisms. In particular, in Homo sapiens, sequences
referred to all alternative first exons - exon 2 junctions were
retrieved, while no EST or defined cDNA sequences matching
alternative first exons - exon 3 junctions were identified, possibly
suggesting their low expression. Many ESTs containing exon 1 or
1c - exon 2 sequences were assigned to RCAN3-1,2,3,4,5 and
RCAN3-1c,2,3,4,5 cDNAs, respectively (Table 2). With the
exception of RCAN3-1,2,4,5 and RCAN3-1c,2,4,5, no human ESTs
referred to previously identified alternative RCAN3 isoforms
[3,20,22] (Figure 1), were retrieved. The low expression level of
previously described alternative isoforms [22] and the absence of
RCAN3 ESTs containing alternative first exons (1, 1c, 1a or 1b)
could explain the difficulty to clone their complete 59 sequences.
Human sequences referred to RCAN3AS isoforms were retrieved,
except for RCAN3AS-1,3 (Table 3). Identical results for RCAN3 and
RCAN3AS genes were obtained using ECgene Browser and
Genome Browser analyses.
Analyses of new RCAN3 isoforms mRNA allowed us to identify
three previously described RCAN3 SNPs [22], already registered in
the single nucleotide polymorphism database. SNPs, now
numbering almost five million entries for the human genome,
are an increasingly important tool for studying the structure and
history of the human genome as well as human diseases [53]. For
all new RCAN3 isoforms the presence of the three SNPs,
responsible of a GRA change, does not modify their predicted
amino acid sequences (Table S1).
On the basis of our previous observation that the RCAN3 gene
appears to be expressed in several tissue types [3], a qualitative
systematic analysis by RT-PCR was performed. We demonstrated
the presence of RCAN3-1a,2,3,4,5, RCAN3-1b,2,3,4,5 and RCA-
N3AS-1,2,3 isoforms in 17 normal human tissues investigated, and
their particular expression in tissues used for cloning experiments,
according to reference EST sources. A qualitative comparison
between RCAN3-1a,2,3,4,5 and RCAN3AS-1,2,3 RT-PCR expres-
sion panels, obtained at the maximum distance from the PCR
reaction plateau, allow us to hypothesize a possible relative
regulation. Similar experiments performed to verify expression of
all isoforms containing exon 1 - exon 2 or exon 1c - exon 2
junctions revealed a similar expression pattern (Figure 3A and B),
thus indicating a stochastic use of exon 1 or exon 1c, as well as in
some known subtle splicing mechanisms. In fact, stochastic splice
site selection during developmental stages or in tissues and
constant splicing ratios indicate that different functions are not
always associated with differential splicing [38].
Particular attention was given to the new evidence of four
RCAN3 alternative non-coding first exons (exon 1, 1c, 1a and 1b),
a phenomenon that adds importance to the complexity of this
mammalian gene structure. Alternative non-coding regulative
regions in 59UTR could be linked to the use of alternative gene
promoters, resulting in tissue-specific or developmental stage-
specific gene expression regulation [54]. In fact, a recent
annotation suggested that almost 50% of the protein-coding genes
contain alternative promoters [55]. Therefore, an analysis of
human RCAN3 genomic sequence was performed to investigate
the possible presence of alternative promoters referred to the
alternative first exons (Figure 5A). Only one CpG island of 202 bp
in length was found by First Exon Finder software upstream and
near the exon 1 start of the RCAN3 gene. The identification by
Promoter Prediction software of three hypothetical short sequenc-
es containing TSSs within the CpG island could allow us to
hypothesize its role as housekeeping gene. In fact, all housekeeping
and widely expressed genes have a CpG island covering the
transcription start, whereas only 40% of the genes with a tissue-
specific or limited expression are associated with islands [56,57].
Although no transcript with first exon 1 or 1c has been obtained
with RACE method, one of the four short sequence containing a
possible TSS (2,964–2,966 nt positions of AL034582) is very close
to the first nucleotide of the reference sequence (NM_013441)
referred to the RCAN3-1,2,3,4,5 isoform. NM_013441 sequence
assembly has been conducted considering the complete 59 RCAN3
sequence derived from a massive sequencing project whose
purpose was to clone full human ORFs from libraries enriched
for full-length cDNAs [24]. Therefore, we could speculate that the
predicted sequence containing the described TSS corresponds to a
possible real transcription start region.
First Exon Finder software detected a promoter region
upstream of exon 1a and ending within the same exon, whose
possible TSS has been verified by RACE method. To date, the
many tests performed with the RACE method allowed us to obtain
only the possible TSS of the RCAN3-1a,2,3,4,5 isoform. The
retrievement of this isoform has been favored by the selected tissue
(prostate) where ‘‘RCAN3-1a’’ isoforms are particularly expressed.
However, further investigations will be needed in order to study
RCAN3 alternative promoters.
Manual analysis of the genomic sequence upstream of exon 1a
revealed a possible guanine repetition responsible of a G-
quadruplex structure formation [40]. G-quadruplexes are four-
stranded DNA structure formed from repetitions of three or four
adjacent guanines (G-tracts) in presence of monovalent cations
such as K
+ and Na
+. Both prokaryotic and eukaryotic genomes
from yeast to man are rich in G-quadruplexes. The highest
occurrence of G-quadruplexes is present in repetitive DNA regions
such as telomeres and, interestingly, up to 40% of human gene
promoters [41]. Furthermore, RNAs are known to form non-
canonical structures such as triple-strands and G-quadruplexes
located in their 59UTRs. The regulated formation of these
structures in the promoter region has been demonstrated to
provide an elegant nucleic-acid-based mechanism for modulating
transcription and translation [41]. A promoter region was not
retrieved upstream of exon 1b by Promoter Prediction software,
but manual analysis underlines the presence of a TATA box and
of a CAAT box at a coherent distance. On the other hand, the
Promoter Prediction software showed a TSS site in a position
plausible with the 59UTR average length of human genes [42]. A
similar analysis of genomic sequences referred to RCAN3AS
isoforms allowed us to identify a possible common promoter
region, a CpG island and a plausible TSS site, upstream of
RCAN3AS exon 1 (Figure 5B). Moreover, the presence of four
alternative RCAN3AS 59UTR and of the shared downstream
coding sequence indicates a possible 59UTR different use, due to a
specific regulative role.
The interest in performing a comparative genomic analysis of
alternative first exons led us to search them in all organisms. Only
sequences similar to human exon 1 - exon 2 (defined cDNAs, but
not EST sequences), human exon 1c - exon 2 and exon 1c - exon 3
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human exon 1 - exon 3, exon 1a - exon 2 or 3 and exon 1b - exon
2 sequences were retrieved, but the possibility of their assembly in
the transcription process could be hypothesized after manual
genomic sequence analyses of some primates and some mammals-
not primates (Table S2). A similar analysis was performed for all
human RCAN3AS isoforms and any relative sequence was
retrieved in other organisms.
The study in Homo sapiens of splice donor sequences for all
possible alternative first exons - first intron - exon 2 or 3 junctions
showed, in all cases, a high sequence conservation compared to the
consensus reference sequence. In particular, the splice donor
sequence is more adherent when isoforms containing exon 1c are
transcribed, compared to isoforms containing exon 1 (Figure S1).
A similar study was performed to analyze RCAN3AS exon 1 - first
intron - alternative exon 2 or exon 3 genomic sequences. In all
sequences, the splice acceptor sequences were very conserved
(Figure S3).
In order to retrieve sequences related to human RCAN3-
1,2,3,4,5 and RCAN3-1c,2,3,4,5 isoforms, a detailed bioinformatic
searches in nr and EST databases were performed in all organisms
(Table S3). With regard to RCAN3-1,2,3,4,5, transcript models
were only found in primates. On the contrary, transcript models
and transcribed sequences referred to RCAN3-1c,2,3,4,5 were
found in primates, mammals - not primates and not mammals
(Table S3, second column). The study of the donor splicing
sequences on all investigated genomic sequences (Table S3, third
column) showed the presence of high sequence conservation
compared to consensus, especially in the exon 1c - exon 2
formation (Figure S2). Moreover, in primates both donor signal
sites were visible on genomic sequences, thus suggesting their
alternative possible use, like it happens in Homo sapiens.I n
mammals-not primates, only the donor splice site corresponding
to human exon 1c was retrieved, with consensus sequence identity
of 100%. In these organisms a splice donor site related to human
exon 1 was not present. Even in organisms not belonging to the
class of mammals (Gallus gallus and Danio rerio), analysis of genomic
sequences indicated that only a splice site similar to human exon
1c, whose signal sequences are highly conserved, would be used.
These genomic contexts, associated with the failure to actually find
transcribed sequences for exon 1 in mammals-not primates and in
not mammals, suggest that in these species there is not the
possibility of alternative use of exon 1 or 1c, but only of an exon
equivalent to human 1c. Therefore, from an evolutionary point of
view, the splice site exon 1c-like appears to be older, as it is the
only one conserved in all species analyzed and characterized by
splice donor sequences that often perfectly match the consensus
sequence, thus indicating a strong splicing signal.
In the present work we have demonstrated the existence of a
complex RCAN3 multi-transcript locus, which consists of 21
alternative RCAN3 isoforms and of 4 isoforms of a new identified
antisense and overlapping gene (RCAN3AS). Analyses of all
transcripts and their putative proteins, of their expression patterns
and of their regulatory non-coding regions, are important to clarify
the genomic structure and the evolutionary pathway of the RCAN3
gene, as well as giving an important basis for further functional
experiments. We think that the discovery and the analysis of
alternative first non-coding exons is of primary interest to study the
regulative role of RCAN3 59UTR in different tissues and/or
specific physiological and pathological cellular conditions. Finally,
the complexity of the RCAN3 locus has been enriched by the newly
identified RCAN3AS gene, whose study could be useful for the
comprehension of RCAN3 gene regulation, as well as for the new
human gene role itself.
Supporting Information
Figure S1 Splice consensus sequences comparison (al-
ternative RCAN3 first exons) in Homo sapiens. The
analysis was carried out for different RCAN3 isoforms aligning
alternative exons 1 - first intron - exon 2 or 3 (according to
considered isoform). CAGGTRAGT: splice donor consensus
sequence; R= purine A/G. YAGN: splice acceptor consensus
sequence; Y= pyrimidine C/T; N= all nucleotides. In bold
black: splicing donor nucleotides identity with consensus sequence
and underlined GT alternative splice signals. In bold white:
splicing acceptor nucleotides identity with consensus sequence. In
bold grey: splicing donor or acceptor nucleotides without identity
with consensus sequence. In bold grey and underlined: purine/
purine or pyrimidine/pyrimidine base pair substitution compared
to consensus sequence.
(XLS)
Figure S2 Splice consensus sequences comparison (al-
ternative RCAN3 exon 1 and 1c) in different species.
* Alternative first exons and exon 2 of studied species were
assembled for similarity with sequences of related species (Homo
sapiens transcript used for Macaca mulatta, Macaca mulatta transcript
used for Callithrix jacchus, Canis lupus familiaris transcript used for
Ailuropoda melanoleuca and Mus musculus transcript used for Rattus
norvegicus). CAGGTRAGT: splice donor consensus sequence; R=
purine A/G. YAGN: splice acceptor consensus sequence; Y=
pyrimidine C/T; N= all nucleotides. Dark grey highlighted:
conserved donor and acceptor splice sequences. In bold black:
splicing donor nucleotides identity with consensus sequence. In
bold white: splicing acceptor nucleotides identity with consensus
sequence and other AG alternative splice signals. In bold grey:
splicing donor or acceptor nucleotides without identity with
consensus sequence. In bold black underlined: ATG start codon.
White block: Primates; light grey block: Mammals, not Primates;
medium grey block: not Mammals.
(XLS)
Figure S3 Splice consensus sequences comparison be-
tween RCAN3AS isoforms in Homo sapiens. RCAN3AS
gene isoforms are on opposite strand compared to RCAN3 gene.
Here relative genomic sequences are reported in 59-39 direction.
CAGGTRAGT: splice donor consensus sequence; R= purine A/
G. YAGN: splice acceptor consensus sequence; Y= pyrimidine
C/T; N= all nucleotides. In bold black: splicing donor
nucleotides identity with consensus sequence. In bold white:
splicing acceptor nucleotides identity with consensus sequence.
Double underlined: exon 2 splice acceptor sequence. Single
underlined: exon 2a splice acceptor sequence. In bold grey:
splicing donor or acceptor nucleotides without identity with
consensus sequence.
(XLS)
Table S1 Single nucleotide polymorphisms (SNPs) of
new RCAN3 isoforms.
a Base pair in brackets referred to the
corresponding GenBank sequence (‘‘GenBank accession no.’’
column).
(PDF)
Table S2 Alternative first exons in other species. Search
was performed in all organisms with BLASTN software (default
parameters, with no filter, excluding Homo sapiens). For all human
RCAN3 isoforms a specific alternative first exon - exon 2 or a
specific alternative first exon - exon 3 query sequences were used.
Manual analysis of found sequences allowed us to assign them to a
specific isoform. ‘‘nr’’ (non redundant), ‘‘nt’’ (nucleotide), ‘‘re-
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tag).
(PDF)
Table S3 RCAN3-1,2,3,4,5 and RCAN3-1c,2,3,4,5 de-
tailed comparison in other species. Search was performed
in all organisms with BLASTN and TBLASTN software (default
parameters, with no filter). Human NM_013441 and NP_038469
were used as initial query sequence to retrieve other organism
transcripts. ‘‘*’’ indicates transcripts attributed to RCAN3-1,2,3,4,5
or RCAN3-1c,2,3,4,5 isoforms after a comparison between genomic
sequence of studied species and reference transcript sequence of a
species evolutionarily related. For different species more complete
retrieved transcript sequence were used as reference to query
refseq_genomic or other genomic sequences databases at NCBI.
Specie-specific exon 1-exon 2 or exon 1c-exon 2 assembly were
used as query to search by BLASTN the specific organism ESTs in
order to prove the expression of the relative isoforms and to
complete the 59 transcript ends. ‘‘nr’’ (non redundant), ‘‘nt’’
(nucleotide), ‘‘EST’’ (human expressed sequence tag).
(PDF)
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